Fig. 6.

PV1019 causes growth inhibition in a panel of colon and ovarian human tumor cell lines that mimics the effect of Chk2 RNAi in ovarian human tumor cells. A, the human colon carcinoma cell lines from the NCI-60 were incubated with varying concentrations of PV1019 for 48 h. The cells were subjected to the sulforhodamine assay and GI₅₀ values were determined. B, the human tumor ovarian cell lines from the NCI-60 were incubated with varying concentrations of PV1019 for 48 h. The cells were subjected to the sulforhodamine B assay and GI₅₀ values were determined. C and D, Chk2 protein levels measured by Western blot in the colon (C) and ovarian (D) cell lines from the National Cancer Institute Developmental Therapeutics Program screen. E, OVCAR-4 cells were transfected with either control siRNA or CHEK2 siRNA and incubated for 96 h in 96-well plates. MTS was added to the plates and the absorbance at 495 nm was measured. Representative experiments are shown. F, OVCAR-8 cells were transfected with either control siRNA or CHEK2 siRNA and incubated for 96 h in 96-well plates. MTS was added to the plates, and the absorbance at 495 nm was measured. Representative experiments are shown.